Study of MBP8298 in Secondary Progressive Multiple Sclerosis (SPMS)

The Multiple Sclerosis (MS) Center of Oregon at Oregon Health & Science University (OHSU) is currently recruiting study subjects to participate in a research trial that will study the effects of MBP8298 in those with diagnosed SPMS.

You may be eligible to participate in this study if you meet all of the following criteria:

• Are between 18 and 65 years old
• Have a diagnosis of SPMS
• Have not had an MS relapse in the last three months

This study requires about 12 visits to OHSU over at least a 2 year period.  You will receive $35 for each completed visit.  The research study will pay for all costs associated with the participation in this study.  You will be responsible for any expenses that have to do with other aspects of your participation, such as childcare or transportation.

If you would like further information about this study, please call the MS Center of Oregon Research Line at (503) 494-7241.

The OHSU MS Center of Oregon in conjunction with the University of California at San Francisco is currently seeking individuals to participate in a research study.  The purpose of the study is to understand the inheritance of MS.

You may qualify if you are:

• Over 13 years of age

• Have MS or a family member has MS

• Willing to receive a one-time blood draw
  

You will not be compensated for participating in this study.  All study related activities will be of no cost to you.

If you or someone you know is interested in participating, please contact the MS Center of Oregon at (503) 494-7241 for more information.

The Multiple Sclerosis (MS) Center of Oregon at Oregon Health & Science University is looking for people with a confirmed diagnosis of MS to participate in a research study that will require several blood draws and saliva collection.  The purpose of the study is to determine the bioavailability of an oral antioxidant, alpha lipoic acid (ALA) in MS patients.

If you are between 18 and 70 years of age, and have a confirmed diagnosis of MS, you may be eligible to participate in this study.

You will not be eligible to participate in this study if you are pregnant or breast feeding, have experienced a relapse in last 30 days, have taken ALA in last 2 weeks, or have a serious health condition other than MS (e.g. anemia, uncontrolled diabetes, cancer, liver disease, lung disease, congestive heart failure).

This study requires two visits to OHSU. The research study will pay for all costs associated with the participation in this study. You will be eligible to receive $50 as a token compensation at the completion of the study. You will be responsible for any expenses that have to do with other aspects of your participation, such as childcare or transportation.

If you meet the eligibility requirements described above and are interested in participating in this study, please call Dr. Vijayshree Yadav at (503) 494-7241.

Ginseng for Multiple Sclerosis Related Fatigue

The MS Center of Oregon is currently recruiting study subjects to enroll in a placebo controlled cross-over design trial that will study the effect of an American Ginseng extract on multiple sclerosis related fatigue.

To enroll in the study, subjects must

Study of Investigational Drug for Multiple Sclerosis

IRB #2426

The Multiple Sclerosis (MS) Center of Oregon at Oregon Health & Science University (OHSU) is currently recruiting study subjects to participate in a research trial that will study the safety of a single dose of an investigational drug for MS.

 You may be eligible to participate in this study if you meet all of the following criteria: 

• Between the ages of 18 and 65

• Have a diagnosis of relapsing remitting or secondary progressive MS

• Have not used a disease-modifying therapy (e.g. recombinant interferon beta, glatiramer acetate) or intravenous steroids in the last month

• Have not had an MS relapse in the last two months

• Do not have a serious health condition other than MS (like heart disease, uncontrolled diabetes mellitus, liver disease or severe psychiatric disorders

 You will receive a single intravenous dose of the study drug.  The intravenous solution may contain the study drug or an inactive substance called a placebo.  You will be assigned by chance (like flipping a coin) to receive study drug or placebo.  There is a 66.7% chance of receiving the study drug and a 33.3% chance of receiving placebo.

 This study requires 9 visits to OHSU over a 3 month period.  One of the visits is a 24 hour stay in the General Clinical Research Center.  The research study will pay for all costs associated with the participation in this study.  You will be responsible for any expenses that have to do with other aspects of your participation, such as childcare or transportation.

If you would like further information about this study, please call the MS Center of Oregon Research Line at (503) 494-7241.

Fish oil as an adjunct therapy for depression in multiple sclerosis and Parkinson’s disease: A Randomized, Placebo-controlled Pilot Study.

The MS Center of Oregon at Oregon Health & Science University is looking for people with a confirmed diagnosis of relapsing remitting MS who are suffering from depression. The purpose of the study is to determine if taking omega-3 fatty acids helps with symptoms of depression in people with MS. In addition we will determine if omega-3 fatty acids decrease blood levels of substances that are associated with MS and depression

You may be eligible to participate in the study if you meet the all of the following criteria:

• 18-85 years old

• Have a diagnosis of MS

• If using disease modifying medications, participant must be on a stable dose at least 6 months prior to enrollment

• On a stable dose of anti-depressant medication

• Have not had an MS relapse or received corticosteroid treatment 1 month prior to enrollment

• Have not eaten more than one 6 oz serving of fish per week 1 month prior to enrollment

• Have not taken fish oil or omega-3 fatty acid supplementation 1 month prior to enrollment

• Not pregnant

• Have no other significant health conditions (like coronary heart disease, uncontrolled diabetes mellitus, liver disease, severe psychiatric disorders)

• Not participating in any other studies

This is a three-month pilot study in which 60 participants will be randomly assigned to receive either fish oil capsules (which have high amounts of omega-3 fatty acids) or placebo oil capsules.

The study requires 3 visits to OHSU. The research study will pay for all costs associated with the participation in this study. You will be responsible for any expenses that have to do with other aspects of your participation such as childcare and transportation.